FDA's Dermatologic Drugs Advisory Committee
Will review Ortho's Retin A (0.05% tretinoin emollient cream) (NDA 19-963) for photodamaged skin and the "general efficacy parameters relative to the assessment of repair of photodamaged skin." On Jan. 24, the committee will assess benzoyl peroxide's continued marketing as an OTC acne product while the ingredient undergoes further safety testing and the National Consumer League request for warning labels on OTC benzoyl peroxide products. Meeting begins at 8:30 a.m. both days in FDA's Parklawn Building, Conference Rooms D & E. . . .
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth